Potent and specific antibiotic combination therapy against Clostridioides difficile

Area of Science:

• Microbiology and Infectious Diseases
• Antibiotic Resistance and Drug Discovery
• Biochemistry and Molecular Biology

Background:

• Keratinicyclins and keratinimicins are novel glycopeptide antibiotics with distinct activities.
• Keratinicyclins possess a unique oxazolidinone moiety, differentiating them from traditional glycopeptides.
• Clostridioides difficile is a significant pathogen, necessitating new therapeutic strategies.

Purpose of the Study:

• To elucidate the mechanism of action of keratinicyclin B (KCB) against Clostridioides difficile.
• To investigate the interaction of KCB with bacterial cell wall components.
• To evaluate the synergistic potential of KCB in combination with vancomycin.

Main Methods:

• Biochemical studies to assess KCB binding to cell wall components.
• Computational modeling to visualize KCB-wall teichoic acid interactions.
• Antimicrobial assays evaluating KCB and vancomycin combinations.

Main Results:

• KCB inhibits C. difficile growth by binding to wall teichoic acids (WTAs), not peptidoglycan termini.
• A computational model revealed KCB utilizes a similar hydrogen-bonding framework to bind WTAs as other glycopeptides use for peptidoglycan.
• KCB and vancomycin (VAN) exhibit significant synergy, achieving complete C. difficile inhibition at nanomolar concentrations.

Conclusions:

• KCB represents a new class of antibiotics targeting WTAs, offering a novel mechanism against C. difficile.
• The combination of KCB and VAN demonstrates potent, specific antimicrobial activity.
• This synergistic combination holds promise for treating C. difficile infections while minimizing impact on commensal microbiota.